Air Force/Texas Coronary Atherosclerosis Prevention study
Last reviewed 01/2018
- randomized controlled trial that enrolled 5608 men (aged 45-73) and 997 postmenopausal women (aged 55-73) with average LDL and total cholesterol levels. The mean total cholesterol for the trial group was 5.71 mmol/l.
- patients were randomized to lovostatin (20-40mg daily) or placebo in addition to a low cholesterol, low saturated fat diet
- after an average follow-up of 5.2 years
- the lovostatin group showed a significant reduction in incidence of acute major coronary events (by 37%), unstable angina (325) and myocardial infarctions (40%).
- the beneficial effects of lovostatin therapy were evident after only one year of the study.
- lovostatin group showed a reduction in LDL cholesterol by 25% and an
increase in HDL cholesterol by 6%
- Conclusions - lovostatin therapy reduced the risk of acute coronary artery events in a trial group with average total and LDL-cholesterols.Treatment benefits were apparent in men and women.
- JAMA (1998), 279, 1615-22.